| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Hyaluronic acid Methacryloyl primarily targets the extracellular matrix components and cell surface receptors such as CD44. It serves as a scaffold material that mimics the natural cellular environment, providing structural support and biochemical signals that influence cell adhesion, migration, proliferation, and differentiation .
|
|---|---|
| ln Vitro |
As a biomaterial scaffold, HAMA facilitates the encapsulation and survival of various cell types in vitro. Studies show that when combined with pancreatic extracellular matrix (pECM), HAMA hydrogels significantly promote the development of organoid cultures. It supports cell growth and maintains tissue-specific functions by providing a three-dimensional culture matrix that mimics native tissue architecture .
|
| ln Vivo |
In vivo, HAMA hydrogels are utilized as injectable or implantable scaffolds for regenerative medicine. When crosslinked in situ using UV light and photoinitiators like LAP, they form stable gels that integrate with host tissue. In animal models, these hydrogels have been shown to support tissue repair and regeneration by creating a conducive microenvironment for cell engraftment and host cell infiltration without eliciting strong inflammatory responses .
|
| Enzyme Assay |
A typical non-cell experimental workflow involves dissolving HAMA powder in phosphate-buffered saline (PBS) at 2-5% (w/v) with a photoinitiator such as LAP (0.25% w/v). The solution is then exposed to UV light (365 nm, 5-10 mW/cm2) for 10-60 seconds to induce crosslinking. The resulting hydrogel is characterized for mechanical properties (rheology) and swelling ratio to confirm gelation efficiency .
|
| Cell Assay |
Cells (e.g., stem cells or primary organoids) are mixed with sterile HAMA solution (2-5% w/v) and LAP (0.25% w/v) on ice. The cell-laden mixture is then transferred to a culture plate or 3D printing platform, followed by UV crosslinking for 10-60 seconds. The encapsulated cells are cultured in standard media at 37degC with 5% CO2, with viability assessed via live/dead staining and proliferation tracked over 7-14 days .
|
| Animal Protocol |
For a subcutaneous implantation model, a HAMA prepolymer solution (5% w/v with 0.25% LAP) is injected subcutaneously into the dorsal region of immunocompromised mice. Using a transdermal UV light source (365 nm), the hydrogel is crosslinked in situ for 60 seconds. The resulting hydrogel plug can be explanted at 1, 4, and 8 weeks post-implantation for histological analysis (H&E staining, immunohistochemistry) to assess host tissue response, scaffold degradation, and neovascularization .
|
| ADME/Pharmacokinetics |
HAMA exhibits degradation behavior dependent on hyaluronidase activity, leading to gradual resorption in vivo over weeks to months. The high molecular weight variant (150 kDa) provides controlled degradation kinetics suitable for long-term tissue engineering applications. It is typically stored as a lyophilized powder at -20degC for long-term stability, with reconstituted solutions used immediately.
|
| Toxicity/Toxicokinetics |
HAMA is considered non-toxic based on its hyaluronic acid backbone, which is biodegradable and biocompatible. Cytotoxicity tests (e.g., MTT assay) on HAMA hydrogels show >90% cell viability in culture. Unreacted methacrylate groups may cause mild irritation, but thoroughly washed and purified HAMA (commonly with >95% methacrylation degree) passes ISO 10993-5 standards for medical device safety.
|
| References |
|
| Additional Infomation |
HAMA is a research-grade biomaterial not approved for clinical therapeutic use as a drug, but it is widely employed in advanced preclinical studies including 3D bioprinting, wound healing, and cartilage repair. As a methacrylated polymer, it offers tunable mechanical properties by varying the molecular weight and degree of methacrylation (typically 20-90%), enabling customized hydrogels for specific tissue engineering applications.
|
| Molecular Weight |
150000.00
|
|---|---|
| Appearance |
White to off-white solid powder
|
| Synonyms |
Methacryloylated hyaluronic acid (MW 150 kDa); HAMA (MW 150 kDa)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.0067 mL | 0.0333 mL | 0.0667 mL | |
| 5 mM | 0.0013 mL | 0.0067 mL | 0.0133 mL | |
| 10 mM | 666.6667 nL | 0.0033 mL | 0.0067 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
